Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Standard Lithium Ltd (SLI) vs Viatris Inc (VTRS) Price & Performance

Standard Lithium LtdTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Standard Lithium Ltd vs Viatris Inc — how do they compare? Standard Lithium Ltd trades at $1.58 (market cap $398.07M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 50.3× Standard Lithium Ltd's market cap, and Viatris Inc pays a 2.75% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and Viatris Inc for 57 Days on average.

SLIVTRS
Market Cap
$398.07M$20.03B
Volume
1,564,15514,109,977
Sector
Basic MaterialsHealth
52-Week High
$5.65$18.27
52-Week Low
$1.58$9.74
Typical Hold Time
23 Days57 Days
Enterprise Value
$260.98M$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Standard Lithium Ltd

Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with mixed signals from technical indicators showing bearish moving averages but oversold RSI readings. The company remains pre-revenue with negative profitability metrics (ROE -15.55%, ROA -14.17%) but has shown improving quarterly EPS performance, beating expectations in recent quarters. Recent developments include progress toward a final investment decision for the South West Arkansas lithium project and new customer offtake agreements.

The investment case hinges on successful project execution, with analyst consensus strongly bullish (100% buy ratings) and a $3.83 price target representing 138% upside. Key risks include the pre-revenue status, negative cash flow from operations, and project timeline execution. The stock offers high-risk, high-reward exposure to lithium development with significant government and institutional support.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SLI
100% Buy0% Sell
Avg holding period · 23 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Standard Lithium Ltd

Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.

Read more on SLI →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →